This is consistent with other reported cLIA responses Bortezomib to Gardasil® vaccine [4], [5] and [18]. We previously reported that the HPV 16 and 18 PsV preparations used for the present study demonstrated similar reporter plasmid packaging efficiency [10], so this is unlikely to explain the observed differences. In addition, the measured

PsV NAb titres could have been affected by the amount of L1 protein in the respective PsV preparations. The PsV L1 content has been shown to vary among HPV genotypes [19] and the HPV 16 PsV preparation in our study contained two to three times more L1 than the HPV 18 PsV. Of interest, the infectious unit titre of the HPV 16 PsV was approximately two times higher than that of HPV 18. These factors, as well as the packaging efficiency of the PsV, could have resulted in differences in the measured HPV 16 and 18 antibody levels. In contrast to Gardasil®, the Cervarix® vaccine induces similar antibody levels in women > 18 years of age for both HPV 16 and 18 [20] and antibody levels for both HPV 16 and 18 are higher than those induced by Gardasil®. The significance of the disparities in antibody titres induced by the two vaccines and their

relevance to long-term persistence of vaccine-induced antibodies is unknown, given that very low levels of HPV antibodies have been shown to be protective in animal models [21]. We did not detect higher levels of antibodies DAPT price at 36 months among subjects who were baseline HPV 16 or 18 seropositive, an observation similar to that of Ngan et al. with Cervarix® vaccine [22]. In contrast, Giuliano et al. [18] and Villa et al. [4] reported that baseline seropositive individuals demonstrated significantly higher anti-HPV responses following Gardasil® vaccine than those who were seronegative at baseline. We also were unable to demonstrate a significant difference in antibody responses at 36 months among subjects Terminal deoxynucleotidyl transferase who were baseline HPV 16 or 18

DNA positive vs. negative, similar to the observations of Villa et al. [4]. Giuliano et al. [18] demonstrated that baseline HPV 16 and 18 DNA negative subjects had similar post-vaccine responses as baseline DNA positive subjects, except when subjects were both seropositive and DNA positive at baseline. Opalka et al. [3] reported that baseline HPV DNA positive subjects generally had higher titres at 48 months compared to subjects who were HPV DNA negative at day 0 or month 7. As our study had small numbers of baseline cLIA and PsV NAb seropositive and baseline DNA positive subjects, we lack the statistical power to assess potential differences in antibody responses for these subjects. Given the high baseline HPV 16 and HPV 18 TIgG seropositivity among the study groups, it is unclear if all the detected TIgG antibodies are type-specific and/or neutralizing.